Maria Fernanda Bautista Gonzalez

Mrs. Maria Fernanda Bautista Gonzalez


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
Sylvia Salmun NehmadSylvia Salmun Nehmad
Sylvia Salmun Nehmad
JGJimena Ruiz de Chavez Gascon
Jimena Ruiz de Chavez Gascon
AVAmairani Méndez Vionet
Amairani Méndez Vionet
XTXimena A van Tienhoven
Ximena A van Tienhoven
Ramiro Cabrera CarrancoRamiro Cabrera Carranco
Ramiro Cabrera Carranco
Endometriosis is a chronic proinflammatory pathology characterized by the growth of tissue similar to the endometrium outside the uterus, affecting approximately 5 to 15% of women worldwide. Suffering from endometriosis entails a complex pathophysiological process, significantly impacting the quality of life and reproductive function of affected women; therefore, it must be addressed in a personalized and comprehensive manner, as its management requires a multidisciplinary approach. This article aims to conduct a comprehensive literature review of endometriosis, not only as a pathophysiological condition but also as a significant factor impacting the social, nutritional, and mental well-being of those who experience it. Emphasis is placed on the importance of understanding and assessing the impact of the pathology to provide a better and more comprehensive approach, integrating various alternatives and strategic treatments for the factors involved in its development. The aim is to provide a complete overview of endometriosis, from its pathophysiology to its impact on the quality of life of patients, as well as a review of current treatment options, both pharmacological and alternative, in order to broaden the perspective on the pathology to improve the care of patients with this disease.

Verified
Journal Article
Open access
PDF file
XTXimena A van Tienhoven
Ximena A van Tienhoven
JGJimena Ruiz de Chavez Gascon
Jimena Ruiz de Chavez Gascon
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
JNJosé Antonio sarkis nehme
José Antonio sarkis nehme
ATAriela Aline Souroujon Torun
Ariela Aline Souroujon Torun
Ramiro Cabrera CarrancoRamiro Cabrera Carranco
Ramiro Cabrera Carranco
Vitamin D (VD) is a fat-soluble steroid hormone with essential physiological functions beyond calcium and bone metabolism. In recent years, its role in women’s reproductive health has gained attention, influencing ovarian function, follicular development, endometrial receptivity, and steroid hormone regulation. VD deficiency has been linked to reproductive disorders such as polycystic ovarian syndrome (PCOS), endometriosis, and infertility. Studies indicate that up to 40–50% of healthy pregnant women have insufficient VD levels, which may contribute to adverse pregnancy outcomes and reduced fertility. With growing evidence connecting VD to reproductive health, this review examines its molecular and endocrine mechanisms in fertility, endometriosis, and PCOS. It explores VD’s therapeutic potential and its implications for improving clinical approaches and future research in reproductive medicine. Maintaining adequate VD levels is crucial for ovarian function, immune modulation in reproductive tissues, and overall fertility. Its deficiency is associated with insulin resistance, hormonal imbalances, and inflammatory processes, which contribute to reproductive pathophysiology. Establishing reference values for VD in reproductive medicine is essential for optimizing fertility treatments and improving clinical outcomes. This review synthesizes current research on VD’s role in reproductive health and highlights the need for further investigation into its therapeutic applications.

2 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
FELIPE ESPARZA SALAZARFELIPE ESPARZA SALAZAR
FELIPE ESPARZA SALAZAR
RPRenata Murguiondo Pérez
Renata Murguiondo Pérez
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
MGMaria Fernanda Bautista Gonzalez
Maria Fernanda Bautista Gonzalez
ELEricka Cristina Loza Lopez
Ericka Cristina Loza Lopez
Antonio IbarraAntonio Ibarra
Antonio Ibarra
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid progression, profound heterogeneity, and resistance to conventional therapies. This review provides an integrated overview of GBM’s pathophysiology, highlighting key mechanisms such as neuroinflammation, genetic alterations (e.g., EGFR, PDGFRA), the tumor microenvironment, microbiome interactions, and molecular dysregulations involving gangliosides and sphingolipids. Current diagnostic strategies, including imaging, histopathology, immunohistochemistry, and emerging liquid biopsy techniques, are explored for their role in improving early detection and monitoring. Treatment remains challenging, with standard therapies—surgery, radiotherapy, and temozolomide—offering limited survival benefits. Innovative therapies are increasingly being explored and implemented, including immune checkpoint inhibitors, CAR-T cell therapy, dendritic and peptide vaccines, and oncolytic virotherapy. Advances in nanotechnology and personalized medicine, such as individualized multimodal immunotherapy and NanoTherm therapy, are also discussed as strategies to overcome the blood–brain barrier and tumor heterogeneity. Additionally, stem cell-based approaches show promise in targeted drug delivery and immune modulation. Non-conventional strategies such as ketogenic diets and palliative care are also evaluated for their adjunctive potential. While novel therapies hold promise, GBM’s complexity demands continued interdisciplinary research to improve prognosis, treatment response, and patient quality of life. This review underscores the urgent need for personalized, multimodal strategies in combating this devastating malignancy.

4 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
XTXimena A van Tienhoven
Ximena A van Tienhoven
JGJimena Ruiz de Chavez Gascon
Jimena Ruiz de Chavez Gascon
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
JNJosé Antonio sarkis nehme
José Antonio sarkis nehme
ATAriela Aline Souroujon Torun
Ariela Aline Souroujon Torun
Ramiro Cabrera CarrancoRamiro Cabrera Carranco
Ramiro Cabrera Carranco
Vitamin D (VD) is a fat-soluble steroid hormone with crucial physiological functions beyond calcium and bone metabolism. In recent years, the role of VD in women’s reproductive health has garnered significant attention. It has been implicated in ovarian function, follicular development, endometrial receptivity, and the regulation of steroid hormone production. VD deficiency has been associated with a range of reproductive health disorders, including Polycystic Ovarian Syndrome (PCOS), endometriosis, and infertility. Studies indicate that up to 40-50% of healthy pregnant women exhibit deficient serum VD levels, which may be linked to adverse pregnancy outcomes and impaired fertility. VD plays a key role in regulating ovarian function, promoting proper follicular development, and modulating the immune response in reproductive tissues. Its deficiency has been linked to insulin resistance, hormonal imbalances, and inflammatory processes, all of which contribute to the pathophysiology of reproductive disorders. This review synthesizes current research on VD's therapeutic potential in managing these disorders and enhancing fertility outcomes, emphasizing the importance of maintaining adequate VD levels for optimal reproductive health. Understanding the reference values for VD in reproductive medicine is essential for optimizing fertility treatments and improving clinical outcomes in women with reproductive health disorders.

26 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
ELEricka Cristina Loza Lopez
Ericka Cristina Loza Lopez
MGMaria Fernanda Bautista Gonzalez
Maria Fernanda Bautista Gonzalez
FELIPE ESPARZA SALAZARFELIPE ESPARZA SALAZAR
FELIPE ESPARZA SALAZAR
TGTamara Mena Guerrero
Tamara Mena Guerrero
ABAna Gabriela Sierra Brozon
Ana Gabriela Sierra Brozon
Endometriosis is a systemic, estrogen dependent neuroinflammatory-mediated disease affecting approximately 10-15% of women of reproductive age. Clinical manifestations include chronic pelvic pain (CPP), dysmenorrhea, dyspareunia, dyschezia, dysuria, and infertility. Endometriosis-associated pain is multifactorial and comprises overlapping nociceptive, neuropathic, and nociplastic pain phenotypes driven by persistent inflammation, neuroangiogenesis, peripheral nerve involvement, and central sensitization (CS). These mechanisms may sustain pain beyond lesion excision, highlighting the importance of pelvic nervous system (PNS) involvement. This narrative review examines the role of neuropelveology (NP) in endometriosis, focusing on pain mechanisms, diagnostic implications, and surgical decision making. NP integrates pelvic neuroanatomy and neurophysiology into structured neurological assessment, pain mapping, symptom localization, and nerve sparing surgery. Current evidence suggests that NP may complement conventional evaluation in selected patients with refractory pain, neuropathic symptoms, discordance between symptom severity and imaging findings, or suspected involvement of the sacral plexus or sciatic nerve. Recognizing distinct pain phenotypes may support individualized treatment planning by balancing lesion excision with neural preservation and identifying patients who may benefit from multidisciplinary pain management, rehabilitation, neurolysis, or neuromodulation. Although current evidence remains limited, NP should be considered a complementary framework rather than a replacement for established endometriosis management. Prospective multicenter studies using standardized diagnostic criteria and long-term functional outcomes are needed to define its clinical utility.

21 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
ELEricka Cristina Loza Lopez
Ericka Cristina Loza Lopez
MGMaria Fernanda Bautista Gonzalez
Maria Fernanda Bautista Gonzalez
FELIPE ESPARZA SALAZARFELIPE ESPARZA SALAZAR
FELIPE ESPARZA SALAZAR
TGTamara Mena Guerrero
Tamara Mena Guerrero
ABAna Gabriela Sierra Brozon
Ana Gabriela Sierra Brozon
Endometriosis is a systemic, estrogen dependent neuroinflammatory-mediated disease affecting approximately 10–15% of women of reproductive age. Clinical manifestations include chronic pelvic pain (CPP), dysmenorrhea, dyspareunia, dyschezia, dysuria, and infertility. Endometriosis-associated pain is multifactorial and comprises overlapping nociceptive, neuropathic, and nociplastic pain phenotypes driven by persistent inflammation, neuroangiogenesis, peripheral nerve involvement, and central sensitization (CS). These mechanisms may sustain pain beyond lesion excision, highlighting the importance of pelvic nervous system (PNS) involvement. This narrative review examines the role of neuropelveology (NP) in endometriosis, focusing on pain mechanisms, diagnostic implications, and surgical decision making. NP integrates pelvic neuroanatomy and neurophysiology into structured neurological assessment, pain mapping, symptom localization, and nerve sparing surgery. Current evidence suggests that NP may complement conventional evaluation in selected patients with refractory pain, neuropathic symptoms, discordance between symptom severity and imaging findings, or suspected involvement of the sacral plexus or sciatic nerve. Recognizing distinct pain phenotypes may support individualized treatment planning by balancing lesion excision with neural preservation and identifying patients who may benefit from multidisciplinary pain management, rehabilitation, neurolysis, or neuromodulation. Although current evidence remains limited, NP should be considered a complementary framework rather than a replacement for established endometriosis management. Prospective multicenter studies using standardized diagnostic criteria and long-term functional outcomes are needed to define its clinical utility.